AlgoTx develops innovative solutions for complex pain. ATX01 is in Ph 2 in chemotherapy-induced peripheral neuropathy (CIPN, ACT study - recruiting) under Fast-Track and ODD designations. There is no approved treatment for CIPN. ATX01 will be the first treatment to relieve the pain of CIPN known to affect 60% of chemotherapy patients. ATX01 is also in Ph 2 in the rare disease erythromelalgia (EM, EASE study - recruiting) under Fast-Track and ODD designations. There is no approved treatment for EM. Both studies will read out in 2024. AlgoTx raised 35 M€ to date, including a 19 M€ Series B in March 2023 led by a syndicate of 4 European funds. AlgoTx’s focus at BIO Europe is to share progress of its Phase 2 studies, network with peers and potential strategic and financial partners of future growth.